نتایج جستجو برای: certolizumab pegol

تعداد نتایج: 885  

Journal: :Cochrane Database of Systematic Reviews 2017

Journal: :Therapeutics and Clinical Risk Management 2014

2013
Katerina Chatzidionysiou Ronald van Vollenhoven van Vollenhoven

Over the past decade, treatment of rheumatoid arthritis (RA) has been revolutionized with the introduction of biological disease-modifying antirheumatic drugs (DMARDs), such as TNF inhibitors (e.g., infliximab, etanercept, adalimumab, golimumab and certolizumab pegol), the IL-6 receptor inhibitor tocilizumab, the chimeric anti-CD20 monoclonal antibody rituximab and the T-cell costimulation inhi...

Journal: :Bulletin of the NYU hospital for joint diseases 2010
Ismail Simsek

The development of tumor necrosis factor (TNF) inhibitor therapy has revolutionized the treatment of rheumatoid arthritis (RA). Unfortunately, no one single agent is fully effective in every patient; different patients respond to different therapies in different ways, even to those agents with the same mechanism of action. In this regard, newer TNF inhibitor agents, such as golimumab and certol...

Journal: :Cochrane Database of Systematic Reviews 2019

2017
Désirée van der Heijde Maxime Dougados Robert Landewé Joachim Sieper Walter P. Maksymowych Martin Rudwaleit Filip Van den Bosch Jürgen Braun Philip J. Mease Alan J. Kivitz Jessica Walsh Owen Davies Lars Bauer Bengt Hoepken Luke Peterson Atul Deodhar

Objective The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. Methods RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a cli...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید